These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. de Fiebre CM; Meyer EM; Henry JC; Muraskin SI; Kem WR; Papke RL Mol Pharmacol; 1995 Jan; 47(1):164-71. PubMed ID: 7838125 [TBL] [Abstract][Full Text] [Related]
23. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Kem WR Behav Brain Res; 2000 Aug; 113(1-2):169-81. PubMed ID: 10942043 [TBL] [Abstract][Full Text] [Related]
24. Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus. Matsuyama S; Matsumoto A; Enomoto T; Nishizaki T Eur J Neurosci; 2000 Oct; 12(10):3741-7. PubMed ID: 11029644 [TBL] [Abstract][Full Text] [Related]
25. Activation of α7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents Aß-mediated inhibition of LTP in the rat hippocampus. Ondrejcak T; Wang Q; Kew JN; Virley DJ; Upton N; Anwyl R; Rowan MJ Eur J Pharmacol; 2012 Feb; 677(1-3):63-70. PubMed ID: 22200627 [TBL] [Abstract][Full Text] [Related]
26. The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Damaj MI; Meyer EM; Martin BR Neuropharmacology; 2000 Oct; 39(13):2785-91. PubMed ID: 11044748 [TBL] [Abstract][Full Text] [Related]
27. Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. Dinklo T; Shaban H; Thuring JW; Lavreysen H; Stevens KE; Zheng L; Mackie C; Grantham C; Vandenberk I; Meulders G; Peeters L; Verachtert H; De Prins E; Lesage AS J Pharmacol Exp Ther; 2011 Feb; 336(2):560-74. PubMed ID: 21084390 [TBL] [Abstract][Full Text] [Related]
28. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Freedman R; Olincy A; Buchanan RW; Harris JG; Gold JM; Johnson L; Allensworth D; Guzman-Bonilla A; Clement B; Ball MP; Kutnick J; Pender V; Martin LF; Stevens KE; Wagner BD; Zerbe GO; Soti F; Kem WR Am J Psychiatry; 2008 Aug; 165(8):1040-7. PubMed ID: 18381905 [TBL] [Abstract][Full Text] [Related]
29. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Tregellas JR; Tanabe J; Rojas DC; Shatti S; Olincy A; Johnson L; Martin LF; Soti F; Kem WR; Leonard S; Freedman R Biol Psychiatry; 2011 Jan; 69(1):7-11. PubMed ID: 20728875 [TBL] [Abstract][Full Text] [Related]
30. Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus. Fujii S; Sumikawa K Brain Res; 2001 Mar; 894(2):347-53. PubMed ID: 11251214 [TBL] [Abstract][Full Text] [Related]
31. Alpha7 nicotinic receptor activation inhibits ethanol-induced mitochondrial dysfunction, cytochrome c release and neurotoxicity in primary rat hippocampal neuronal cultures. Li Y; Meyer EM; Walker DW; Millard WJ; He YJ; King MA J Neurochem; 2002 May; 81(4):853-8. PubMed ID: 12065644 [TBL] [Abstract][Full Text] [Related]
32. Evidence for thymopoietin and thymopoietin/alpha-bungarotoxin/nicotinic receptors within the brain. Quik M; Babu U; Audhya T; Goldstein G Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2603-7. PubMed ID: 1848710 [TBL] [Abstract][Full Text] [Related]
33. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Ji D; Lape R; Dani JA Neuron; 2001 Jul; 31(1):131-41. PubMed ID: 11498056 [TBL] [Abstract][Full Text] [Related]
37. "Weak toxin" from Naja kaouthia is a nontoxic antagonist of alpha 7 and muscle-type nicotinic acetylcholine receptors. Utkin YN; Kukhtina VV; Kryukova EV; Chiodini F; Bertrand D; Methfessel C; Tsetlin VI J Biol Chem; 2001 May; 276(19):15810-5. PubMed ID: 11279130 [TBL] [Abstract][Full Text] [Related]
38. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Qi XL; Nordberg A; Xiu J; Guan ZZ Neurochem Int; 2007; 51(6-7):377-83. PubMed ID: 17493709 [TBL] [Abstract][Full Text] [Related]
39. Rhesus monkey alpha7 nicotinic acetylcholine receptors: comparisons to human alpha7 receptors expressed in Xenopus oocytes. Papke RL; McCormack TJ; Jack BA; Wang D; Bugaj-Gaweda B; Schiff HC; Buhr JD; Waber AJ; Stokes C Eur J Pharmacol; 2005 Nov; 524(1-3):11-8. PubMed ID: 16266703 [TBL] [Abstract][Full Text] [Related]
40. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells. Riganti L; Matteoni C; Di Angelantonio S; Nistri A; Gaimarri A; Sparatore F; Canu-Boido C; Clementi F; Gotti C Br J Pharmacol; 2005 Dec; 146(8):1096-109. PubMed ID: 16273122 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]